Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07252856

Transcultural Digital Solutions in Phase III Cardiac Rehabilitation

Multicenter Prospective Controlled Randomized Trial, open-label, in patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure) and an approved indication for cardiac rehabilitation (CR). Patients completing phase II CR will be randomized 1:1 to usual Phase-III care (standard care) versus standard care plus the Digitally-Enhanced Extended PrEvention & Rehabilitation (DEEPER) package (intervention). Primary outcome is 6-month change in composite Life's Crucial 9 (LC9) (LE8 + PHQ-9).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KU Leuven, Kaatje Goetschalckx, KU Leuven, Leuven, Belgium

Loading trial locations.

About this study

Multicenter Prospective Controlled Randomized Trial, open-label, in patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure) and an approved indication for cardiac rehabilitation (CR). Patients completing phase II CR will be randomized 1:1 to usual Phase-III care (standard care) versus standard care plus the Digitally-Enhanced Extended PrEvention & Rehabilitation (DEEPER) package (intervention). Primary outcome is 6-month change in composite Life's Crucial 9 (LE9) (LE8 + PHQ-9). Intervention (DEEPER) will include informative modules (patient will choose among graphic medicine, video or interactive messaging) that will be delivered every two weeks via secure digital platform (or booklet if offline); monthly motivational messages; moderated peer-support forum with leaderboard; remote wearable step/sleep upload with personalized content assignment and feedback, linked to the hospital interactive digital platform (Rehab companion).

Patients will be encouraged to have their own device to be adopted as lifelong maintenance. Nevertheless, centres will provide a smartwatch (fitbit) to all the patients enrolled in the trial as incentive for study participation and to uniformly collect study outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18, men and women;
  • patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure);
  • patients who completed phase II CR and are therefore eligible for CR phase III (maintenance).

Exclusion criteria

  • Unable to sign the informed consent;
  • unable or unwilling to use digital devices due to mental/cognitive issues or without a support person helping them to access the respective technical devices;
  • pregnant, lactating or women planning pregnancy during the course of the trial.

Treatment and study plan

DEEPER

Behavioral

A transcultural scientific digital platform (Rehab companion, Inselspital, University Hospital of Bern) for content delivery, feedback and digital biomarker monitoring will be made available.

Primary outcomes

  1. 6-month change in composite Life's Essential 9 (LE9)

    Time frame: 6-month change

    LC9 is defined by the American Heart Association's Life's Essential 8 (LE8), complemented by the Patient Health Questionnaire (PHQ-9), collectively referred to as "LC9 [blood pressure, non-high-density lipoprotein cholesterol (HDL), diet questionnaire, physical activity, smoking habits, sleep health, body mass index (BMI), hemoglobin A1c (HbA1c, %), PHQ9 from questionnaire).

Secondary outcomes

  1. Individual LE8 sub-scores

    Time frame: 6-month change

    Reported as differences in the absolute value among the two groups (median and (IQR)

  2. Major adverse cardiovascular event (MACE)

    Time frame: 6 months

    defined as a composite of death of any cause, myocardial infarction, unplanned revascularization, rehospitalization for any cause, stroke, considered in a hierarchical way and as single endpoint

  3. Major adverse cardiovascular event (MACE)

    Time frame: 1 year

    defined as a composite of death of any cause, myocardial infarction, unplanned revascularization, rehospitalization for any cause, stroke, considered in a hierarchical way and as single endpoint

  4. GAD 7

    Time frame: Changes between baseline and 6-month follow-up

    anxiety score; Seven-item questionnaire that assesses the severity of anxiety symptoms over the past two weeks, with a total score ranging from 0 to 21

  5. PHQ 9

    Time frame: Changes between baseline and 6-month follow-up

    depression score; The PHQ-9 score ranges from 0 to 27. Scores between 5 and 9 indicate the presence of subthreshold depression.

  6. Physical fitness

    Time frame: Changes between baseline and 6-month follow-up

    distance achieved in 6-minute walking test

  7. VO2 peak

    Time frame: Changes between baseline and 6-month follow-up

    cardiopulmonary test (CPET)

  8. 30 second sit-to -stand test

    Time frame: Changes between baseline and 6-month follow-up

    number of times the patient stands in 30 seconds

  9. Hand-grip strength

    Time frame: Changes between baseline and 6-month follow-up

    maximum voluntary muscle strength measured by dynamometer

  10. Steps per day

    Time frame: Changes between baseline and 6-month follow-up

    amount of steps during the day

  11. Waist circumference

    Time frame: Changes between baseline and 6-month follow-up

    Waist circumference in cm

  12. counter movement jump test.

    Time frame: Changes between baseline and 6-month follow-up

    Maximum power measured by dynamometer; difference in the absolute value among the two groups

  13. Compliance with study treatment

    Time frame: 6 months

    Compliance with study treatment defined as number (percentage) of patients who will attend the sessions provided and will complete the study.

  14. Economic impact of the CR pathways and financial sustainability: standard care versus stardard care plus the DEEPER package

    Time frame: 6 months

    Direct costs of the two pathways, estimated using Activity Based Costing and financial sustainability measured with a budget impact analysis (BIA). Results reported as mean difference and standard deviation (SD) between groups.

    Cost per patient and cost-effectiveness ratio will be calculated per group of treatment.

  15. Acceptance of the usual care and the DEEPER package pathway using the Service User Technology Acceptance Questionnaire (SUTAQ) average values

    Time frame: 6 months

    Responses to SUTAQ-based questionnaire administered to patients involved in the study, analyzed through a seven items scale scoring. Results reported as mean, p-value and linear regression models for enhanced care, increased accessibility, privacy and discomfort, care personnel concerns, telerehabilitation as substitution and satisfaction.

  16. Assessment of social, ethical and equity dimensions.

    Time frame: 6 months

    Perceptions reported by the patients, measured with a seven item Likert scale structured questionnaire based on the EUnetHTA Core Model dimensions, comparing standard care versus DEEPER package (mean and p-value)

  17. Social costs

    Time frame: 6 months

    Analysis of the indirect and out of pocket costs as average value in case of standard care and DEEPER package, to define the social costs related to the interventions.

  18. Safety endpoint

    Time frame: 6 months

    Musculo-skeletal injuries (requiring medical attention) and Arrhythmias (atrial fibrillation, supraventricular tachycardia, ventricular tachycardia) requiring medical attention and an emergency room or ambulatory visit.

Study contacts

Contact information is provided by the study sponsor or research team.

Anastasia Toccafondi

CONTACT

[email protected]

Nuccia Morici, MD

CONTACT

[email protected]

00390240308519

Sponsors and collaborators

Lead sponsor

Fondazione Don Carlo Gnocchi ETS

Other

Registry information

Official study title

CrOss-cultural Model for Postdischarge Assistance and Sustainable Digital Solutions in Phase III Cardiac Rehabilitation: a Randomized Controlled Trial

Acronym: COMPASS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 28, 2025
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.